Evidence map›Paper›PMID 41448791›Full record

Observational studyBMJ open respiratory research2025

Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard.

Ieuan Edward Shepherd Evans, Daniel Smith, Daniel Henderson, Timothy Riddles, Philip Masel, Vanessa Moore, Andrew J Burke, Rachel M Thomson, David W Reid

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ieuan Edward Shepherd EvansFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia ieuan.evans@uq.edu.au.ORCID http://orcid.org/0000-0002-9669-0805
Daniel SmithDepartment of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Daniel HendersonDepartment of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Timothy RiddlesDepartment of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Philip MaselFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Vanessa MooreDepartment of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Andrew J BurkeFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Rachel M ThomsonFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
David W ReidDepartment of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prevalence of infection with non-tuberculous mycobacteria (NTM) has been increasing in people with cystic fibrosis (pwCF) over the past 30 years. Emerging reports of beneficial effects of

methodsWe examined the impact of ETI introduction on rates of NTM isolation in pwCF attending an adult CF centre and two large regional clinics providing CF care. Data on NTM infection were collected for a minimum of 2 years pre- and post-initiation of ETI.

resultsIn total, 271 (84.2%) were commenced on ETI with 33 (12.2%) of these pwCF isolating an NTM species on one or more occasion. The number of pwCF isolating

conclusionsETI therapy was not associated with reduced rates of NTM isolation from sputum over the first 2 years of treatment. However, at a species level, two distinct patterns of change were seen with a trend towards a reduction in the isolation of

Indexed as

AminophenolsBenzodioxolesCystic FibrosisIndolesMycobacterium Infections, NontuberculousPyrazolesPyridinesQuinolinesAdultChloride Channel AgonistsDrug CombinationsFemaleHumansMaleNontuberculous MycobacteriaPrevalenceAminophenolsBenzodioxolesChloride Channel AgonistsDrug Combinationselexacaftor, ivacaftor, tezacaftor drug combinationIndolesPyrazolesPyridinesQuinolinesAtypical Mycobacterial InfectionCystic FibrosisOpportunist lung infectionsRespiratory Infection

Identifiers

PMID41448791
PMCPMC12742134

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.